Kentucky is currently home to 1027 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ROSE-Longitudinal Assessment With Neuroimaging
NCT05089331
Recruiting
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2023
Locations: Baptist Health Louisville, Louisville, Kentucky
Conditions: Intracerebral Hemorrhage
Register for Updates
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04921345
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
04/05/2023
Locations: Galderma Investigational Site #8092, Louisville, Kentucky
Conditions: Moderate-to-Severe Atopic Dermatitis
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: University of Kentucky A.B.Chandler Medical Center, Lexington, Kentucky
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: Merkel Cell Carcinoma
Register for Updates
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
NCT02075775
Recruiting
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiogra... Read More
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
11/07/2022
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Orthopaedic Institute of Western Kentucky, Paducah, Kentucky
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
CERENOVUS Neurothrombectomy Devices Registry
NCT05591183
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2022
Locations: Norton Neurology Institute, Elizabethtown, Kentucky
Conditions: Cerebral Stroke
Register for Updates
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
NCT04669548
Recruiting
The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2022
Locations: Jewish Hospital / University of Louisville, Louisville, Kentucky
Conditions: Intraabdominal Hypertension, Abdominal Compartment Syndrome, Acute Kidney Injury, Cardiovascular Surgery
Register for Updates
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
NCT04845217
Recruiting
The purpose of this study is to assess the use of peppermint oil as a treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
08/19/2022
Locations: Springs Medical Center, Louisville, Kentucky
Conditions: Interstitial Cystitis
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Kentucky Medical Center, Lexington, Kentucky
Conditions: Breast Cancer
Register for Updates
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
NCT04270591
Recruiting
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2022
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: C-Met Exon 14 Mutation
Register for Updates
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT05037825
Recruiting
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods are needed to understand how microbiota and their byproducts affect cancer therapies, particularly a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2022
Locations: Baptist Health Clinical Research, Elizabethtown, Kentucky
Conditions: Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
Register for Updates